Ensysce Biosciences (ENSC) Registration filing summary

Company overview and business model

• Operates in the biosciences sector, focusing on the development and commercialization of pharmaceutical products.

• Principal executive offices located in La Jolla, California.

Financial performance and metrics

• Has incurred substantial losses since inception and expects to continue significant losses as R&D and regulatory approval efforts continue.

• Current cash on hand is sufficient to fund operations into Q2 2026; substantial doubt exists about ability to continue as a going concern.

• Stock price has been highly volatile, ranging from $0.314 to $4.85 per share over the past year.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling securityholders.

• Will receive net proceeds only from the exercise of warrants for cash, to be used for working capital and general corporate purposes.